ACCESS Newswire

The Gross Law Firm

19.7.2021 21:52:39 CEST | ACCESS Newswire | Press release

Share
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of PRVB, OCGN and DKNG

NEW YORK, NY / ACCESSWIRE / July 19, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Provention Bio, Inc. (NASDAQ:PRVB)

Investors Affected: November 2, 2020 - April 8, 2021

A class action has commenced on behalf of certain shareholders in Provention Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/provention-bio-inc-loss-submission-form/?id=17782&from=1

Ocugen, Inc. (NASDAQ:OCGN)

Investors Affected: February 2, 2021 - June 10, 2021

A class action has commenced on behalf of certain shareholders in Ocugen, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/ocugen-inc-loss-submission-form/?id=17782&from=1

DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. (NASDAQ:DKNG)

Investors Affected: December 23, 2019 - June 15, 2021

A class action has commenced on behalf of certain shareholders in DraftKings Inc f/k/a Diamond Eagle Acquisition Corp. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) SBTech Global Limited ("SBTech"), a company acquired by DraftKings, had a history of unlawful operations; (ii) accordingly, DraftKings' merger with SBTech exposed the Company to dealings in black-market gaming; (iii) the foregoing increased the Company's regulatory and criminal risks with respect to these transactions; (iv) as a result of all the foregoing, the Company's revenues were, in part, derived from unlawful conduct and thus unsustainable; (v) accordingly, the benefits of the Business Combination were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/draftkings-inc-f-k-a-diamond-eagle-acquisition-corp-loss-submission-form/?id=17782&from=1

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/656142/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-PRVB-OCGN-and-DKNG

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner3.2.2026 11:30:00 CET | Press release

TORONTO, ON AND LONDON, UK / ACCESS Newswire / February 3, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Dr. Christoph Themel as a Partner in the firm's Life Sciences and Healthcare Practice. Based in London, Dr. Themel advises boards, investors, and senior leadership teams on executive and non-executive appointments, leadership assessments, and succession planning across the pharmaceutical, biotechnology, and animal health sectors. Dr. Christoph Themel joins Caldwell as partner in the firm's Life Sciences and Healthcare Practice With more than 20 years of experience in executive search and leadership advisory, Dr. Themel is a trusted advisor to big and mid-sized pharmaceutical companies, family-owned enterprises, private equity firms, and portfolio company leadership teams across Europe, the United States, and Asia Pacific. He is particularly known for his ability to partner closely with shareholders and management teams on C-sui

AI Rises on the Finance Leadership Agenda as Cost Control Dominates 2026, New Survey Reveals3.2.2026 10:00:00 CET | Press release

MANCHESTER, UK / ACCESS Newswire / February 3, 2026 / AccessPay, the leading bank integration provider, today announced the release of its Finance Trends 2026 report, presenting the findings of its annual survey of finance leaders. In this fourth year of the report, AccessPay reveals marked sectoral differences between finance teams in financial services firms and those in corporates with regards to their priorities and attitudes to technology adoption. Key findings from the report include: 1. Finance leaders are prioritising finance efficiency and cost control Finance teams across all sectors are placing renewed emphasis on efficiency and cost control in 2026. 47% of general corporates cited this as a priority, a goal shared by 46% of financial services firms. Although cost control is a perennial concern in financial management, sluggish economic growth, rising costs, and geopolitical turmoil have brought it to the fore. Finance leaders are being pushed to do more with less, which als

Formerra and Evonik Expand Distribution Partnership for Healthcare Grades2.2.2026 15:00:00 CET | Press release

Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications. This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup. With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgi

Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor2.2.2026 13:30:00 CET | Press release

This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire / February 2, 2026 / Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy. Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationw

Formerra to Supply Foster Medical Compounds in Europe29.1.2026 15:00:00 CET | Press release

Expanded agreement infuses Formerra's European healthcare polymer portfolio with life-saving Foster® compounds. PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions. Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye